While Cue Biopharma Inc has underperformed by -1.45%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, CUE fell by -38.31%, with highs and lows ranging from $1.99 to $0.45, whereas the simple moving average fell by -34.87% in the last 200 days.
On March 13, 2024, Jefferies started tracking Cue Biopharma Inc (NASDAQ: CUE) recommending Buy. Piper Sandler also rated CUE shares as ‘Overweight’, setting a target price of $7 on the company’s shares in an initiating report dated November 21, 2022. H.C. Wainwright Initiated an Buy rating on January 13, 2022, and assigned a price target of $20. Craig Hallum initiated its ‘Buy’ rating for CUE, as published in its report on January 03, 2022. Berenberg’s report from November 24, 2020 suggests a price prediction of $30 for CUE shares, giving the stock a ‘Buy’ rating. Stifel also rated the stock as ‘Buy’.
Analysis of Cue Biopharma Inc (CUE)
Further, the quarter-over-quarter decrease in sales is -75.48%, showing a negative trend in the upcoming months.
One of the most important indicators of Cue Biopharma Inc’s future performance is equity, which can be evaluated using several well-rounded types of analysis and research techniques. The goal here is to ensure that your current return on equity of -221.66% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 1.03, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
For any stock, average volume can also provide valuable insight into volatility, and CUE is recording 216.17K average volume. On a monthly basis, the volatility of the stock is set at 10.50%, whereas on a weekly basis, it is put at 11.06%, with a loss of -7.04% over the past seven days. Furthermore, long-term investors anticipate a median target price of $4.00, showing growth from the present price of $0.67, which can serve as yet another indication of whether CUE is worth investing in or should be passed over.
How Do You Analyze Cue Biopharma Inc Shares?
Along with the fundamentals, it is also important to consider how many employees own shares of the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 0.75%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 16.46% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
CUE shares are owned by institutional investors to the tune of 16.46% at present.
